Nebenwirkungen · Krazati
KRAZATI 200 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8–9
HOS-150732 · Präparat HOS-100372
8 Hepatotoxicity Hepatotoxicity-related reactions were reported in 41.0% (all grades) and 11.3% (Grade ≥ 3) of patients treated with adagrasib. Elevations of ALT occurred in 28.3% of patients and elevations of AST in 29.0% of patients. Grade ≥ 3 elevations of ALT and AST each occurred in 6.6% and 4.6% of patients, respectively. Liver injury has been reported in < 1% of patients. Median time to first onset of adverse reactions was 22 days for ALT and AST increased, 63 days for blood bilirubin increased and 22 days for blood alkaline phosphatase increased, with a median duration of 22, 13 and 35 days, respectively.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-21T10:08:00Z · SHA-256 7b80e4bc7f6f1531858ad427e6ad8622b4c29caf51f3d5c29749df0a28c1f63b · Passage 8a52f1c5a2381777478deb29afe4848a00449eed08f3e8cda376c2db8ebea7ee · Zeichen 6463–7084 im Abschnitt